Immunocore (IMCR) Competitors $32.42 -0.14 (-0.43%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMCR vs. BPMC, NUVL, CYTK, VKTX, LNTH, CRNX, RNA, KRYS, ADMA, and TGTXShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Blueprint Medicines (BPMC), Nuvalent (NUVL), Cytokinetics (CYTK), Viking Therapeutics (VKTX), Lantheus (LNTH), Crinetics Pharmaceuticals (CRNX), Avidity Biosciences (RNA), Krystal Biotech (KRYS), ADMA Biologics (ADMA), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. Blueprint Medicines Nuvalent Cytokinetics Viking Therapeutics Lantheus Crinetics Pharmaceuticals Avidity Biosciences Krystal Biotech ADMA Biologics TG Therapeutics Blueprint Medicines (NASDAQ:BPMC) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Do analysts prefer BPMC or IMCR? Blueprint Medicines currently has a consensus target price of $122.11, indicating a potential upside of 28.79%. Immunocore has a consensus target price of $69.18, indicating a potential upside of 113.39%. Given Immunocore's higher probable upside, analysts plainly believe Immunocore is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 2.71Immunocore 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.62 Does the media prefer BPMC or IMCR? In the previous week, Blueprint Medicines had 22 more articles in the media than Immunocore. MarketBeat recorded 27 mentions for Blueprint Medicines and 5 mentions for Immunocore. Immunocore's average media sentiment score of 1.42 beat Blueprint Medicines' score of 0.66 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 10 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor BPMC or IMCR? Blueprint Medicines received 470 more outperform votes than Immunocore when rated by MarketBeat users. However, 73.56% of users gave Immunocore an outperform vote while only 68.03% of users gave Blueprint Medicines an outperform vote. CompanyUnderperformOutperformBlueprint MedicinesOutperform Votes53468.03% Underperform Votes25131.97% ImmunocoreOutperform Votes6473.56% Underperform Votes2326.44% Do insiders & institutionals have more ownership in BPMC or IMCR? 84.5% of Immunocore shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 9.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is BPMC or IMCR more profitable? Immunocore has a net margin of -15.87% compared to Blueprint Medicines' net margin of -29.48%. Immunocore's return on equity of -12.84% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-29.48% -112.30% -26.87% Immunocore -15.87%-12.84%-5.09% Which has stronger valuation & earnings, BPMC or IMCR? Immunocore has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$249.38M24.15-$506.98M-$2.11-44.93Immunocore$296.31M5.47-$55.29M-$0.95-34.13 Which has more volatility & risk, BPMC or IMCR? Blueprint Medicines has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. SummaryImmunocore beats Blueprint Medicines on 13 of the 19 factors compared between the two stocks. Ad Behind the Markets📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.62B$2.93B$5.01B$8.81BDividend YieldN/A1.89%5.16%4.06%P/E Ratio-34.1345.25134.3717.77Price / Sales5.47360.241,158.6875.18Price / CashN/A160.0933.5332.53Price / Book4.373.734.674.68Net Income-$55.29M-$41.63M$119.07M$226.08M7 Day Performance-0.61%-4.73%-1.83%-1.04%1 Month Performance-2.67%-6.53%-3.62%1.04%1 Year Performance-28.19%25.63%31.63%26.28% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore3 of 5 stars$32.42-0.4%$69.18+113.4%-28.7%$1.62B$296.31M-34.13497Positive NewsBPMCBlueprint Medicines2.7079 of 5 stars$94.81+0.2%$122.11+28.8%+43.9%$6.02B$249.38M-44.93640Analyst ForecastNUVLNuvalent2.1677 of 5 stars$91.17+0.1%$112.60+23.5%+51.1%$5.90BN/A0.0040CYTKCytokinetics3.8052 of 5 stars$49.86-2.4%$83.67+67.8%+54.3%$5.88B$3.22M-9.27250Analyst ForecastInsider TradeOptions VolumeNews CoverageVKTXViking Therapeutics4.7706 of 5 stars$51.53+0.0%$109.80+113.1%+337.8%$5.74BN/A0.0020Analyst ForecastGap UpLNTHLantheus4.5262 of 5 stars$86.45+8.8%$122.50+41.7%+25.1%$5.52B$1.30B14.38834Positive NewsGap UpCRNXCrinetics Pharmaceuticals3.5524 of 5 stars$56.07+1.6%$70.18+25.2%+85.5%$5.20B$4.01M-15.03210Analyst RevisionRNAAvidity Biosciences2.3883 of 5 stars$43.65+0.9%$63.22+44.8%+631.2%$5.16B$9.56M0.00190Insider TradeAnalyst RevisionKRYSKrystal Biotech4.8348 of 5 stars$178.10+0.1%$202.29+13.6%+70.0%$5.12B$50.70M100.62229Positive NewsADMAADMA Biologics3.3139 of 5 stars$21.37+3.6%$21.25-0.6%+430.3%$5.05B$258.21M75.68530TGTXTG Therapeutics4.2148 of 5 stars$31.15+2.7%$37.67+20.9%+143.0%$4.85B$233.66M-311.47290Positive News Related Companies and Tools Related Companies BPMC Competitors NUVL Competitors CYTK Competitors VKTX Competitors LNTH Competitors CRNX Competitors RNA Competitors KRYS Competitors ADMA Competitors TGTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMCR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
